Menu
Search
|

Menu

Close
X

Acer Therapeutics Inc ACER.OQ (NASDAQ Stock Exchange Capital Market)

24.36 USD
+0.00 (+0.00%)
As of Nov 13
chart
Previous Close 24.36
Open 24.00
Volume 3,553
3m Avg Volume 12,848
Today’s High 25.29
Today’s Low 24.00
52 Week High 34.10
52 Week Low 11.45
Shares Outstanding (mil) 10.05
Market Capitalization (mil) 243.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
1
FY15
3
EPS (USD)
FY18
-1.610
FY17
-2.303
FY16
-9.615
FY15
-23.521
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
--
15.43
Price to Book (MRQ)
vs sector
4.58
4.06
Price to Cash Flow (TTM)
vs sector
--
21.23
Total Debt to Equity (MRQ)
vs sector
0.00
14.84
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-50.09
12.77
Return on Equity (TTM)
vs sector
-50.09
14.47

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One Gateway Center (300 Washingt
Suite 351
NEWTON   MA   02458

Phone:

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

SPONSORED STORIES